✦ LIBER ✦

Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis

✍ Scribed by Kausik Umanath; Mohammed Sika; Robert Niecestro; Carolyn Connelly; Gerald Schulman; Mark J. Koury; Julia B. Lewis; Jamie P. Dwyer; Collaborative Study Group

Book ID: 114764303
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 154 KB
Volume: 17
Category: Article
ISSN: 1492-7535
DOI: 10.1111/j.1542-4758.2012.00711.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

292 A Dose-Ranging and Efficacy Phase 3

292 A Dose-Ranging and Efficacy Phase 3 Trial of Ferric Citrate (FC) as a Phosphate Binder in Dialysis Patients

✍ Mohammed Sika; Mark Smith; Gerald Schulman; Mark Kaplan; Julia Lewis 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 240 KB

Rationale, design and baseline character

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

✍ Ridderstråle, Martin; Svaerd, Robbyna; Zeller, Cordula; Kim, Gabriel; Woerle, Ha 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 289 KB